The Patent Finder

Pact Pharma, Inc.

0 patents currently held · Updated Nov 22, 2026
11 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
none
Next term end

When these terms end

Held patents by the year their term ends
2026 · 0 end2027 · 02028 · 02029 · 02030 · 0

Fee deadlines

No maintenance fee falls due on this company's record before Nov 22, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

No patent on this record is in force and held under this name now.

Also on record: 11 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

5 pending · 5 abandoned

Showing 1 to 10 of 10, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page.

ApplicationTitleFiledStatus
18/332,169Methods of Treatment Using a Genetically Modified Autologous T Cell ImmunotherapyJun 9, 2023Pending
18/319,743COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A TGFßRII ENGINEERED T CELL THERAPYMay 18, 2023Pending
18/306,927Compositions and Methods for the Treatment of Cancer Using Next Generation Engineered T Cell TherapyApr 25, 2023Pending
18/049,114Methods of Determining Gene Editing Eficiencies in CellsOct 24, 2022Pending
17/487,411Personalized Neoantigen-Specific Adoptive Cell TherapiesSep 28, 2021Pending
17/400,974Primary Cell Gene EditingAug 12, 2021Abandoned
17/099,192Methods of Treatment Using a Genetically Modified Autologous T Cell ImmunotherapyNov 16, 2020Abandoned
17/099,140Compositions and Methods for the Treatment of Cancer Using a TET2 Engineered T Cell TherapyNov 16, 2020Abandoned
17/067,101Method of Treating Immunotherapy Non-Responders with an Autologous Cell TherapyOct 9, 2020Abandoned
16/893,166Primary Cell Gene EditingJun 4, 2020Abandoned
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited